Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoJect for Intradermal Rabies Immunization
NCT02538185Phase 1Completed
- Sponsor
- Lausanne University Hospital
- Start
- Aug 2013
- Primary completion
- Sep 2014
01
Overview
Phase 1, randomised, double-blind trial (3 arms), sponsored by Lausanne University Hospital. Primary endpoints: Number of Adverse Events as a Measure of Safety and Tolerability at Day 56, Pain Scores at needle insertion and at product injection at Day 28 and 3 more. Started Aug 2013; status: completed.
Beyond the preview
Go deeper on NCT02538185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538185.